Wells Fargo & Company reiterated their market perform rating on shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in a report released on Thursday.

Several other research analysts have also issued reports on the stock. Vetr raised shares of Teva Pharmaceutical Industries Limited from a sell rating to a hold rating and set a $32.27 price target for the company in a research report on Wednesday, June 28th. Royal Bank Of Canada reissued an outperform rating and issued a $37.00 price target (down previously from $38.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Monday, July 17th. Zacks Investment Research raised shares of Teva Pharmaceutical Industries Limited from a strong sell rating to a hold rating in a research report on Wednesday. Goldman Sachs Group, Inc. (The) reissued a neutral rating and issued a $21.00 price target (down previously from $28.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, August 31st. Finally, BTIG Research raised shares of Teva Pharmaceutical Industries Limited from a neutral rating to a buy rating and set a $24.00 price target for the company in a research report on Monday, September 11th. Five investment analysts have rated the stock with a sell rating, eighteen have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $28.72.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up 1.66% during mid-day trading on Thursday, reaching $15.94. The company had a trading volume of 19,658,567 shares. The company’s 50-day moving average price is $16.94 and its 200-day moving average price is $26.89. Teva Pharmaceutical Industries Limited has a 52-week low of $15.22 and a 52-week high of $45.85. The company’s market capitalization is $16.20 billion. Teva Pharmaceutical Industries Limited also was the target of some unusual options trading activity on Wednesday. Stock traders acquired 29,656 put options on the stock. This represents an increase of approximately 231% compared to the typical volume of 8,957 put options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The company had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. During the same quarter in the previous year, the business posted $1.25 EPS. The firm’s quarterly revenue was up 12.9% on a year-over-year basis. On average, analysts forecast that Teva Pharmaceutical Industries Limited will post $4.28 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Teva Pharmaceutical Industries Limited’s (TEVA) Market Perform Rating Reaffirmed at Wells Fargo & Company” was reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/teva-pharmaceutical-industries-limiteds-teva-market-perform-rating-reaffirmed-at-wells-fargo-company/1613789.html.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th were paid a $0.085 dividend. The ex-dividend date of this dividend was Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a yield of 2.13%. Teva Pharmaceutical Industries Limited’s payout ratio is presently -15.36%.

A number of hedge funds have recently made changes to their positions in TEVA. Capital Research Global Investors boosted its stake in Teva Pharmaceutical Industries Limited by 13.8% in the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after acquiring an additional 9,260,426 shares during the last quarter. Franklin Resources Inc. boosted its stake in Teva Pharmaceutical Industries Limited by 11.1% in the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after acquiring an additional 6,685,844 shares during the last quarter. FMR LLC boosted its stake in Teva Pharmaceutical Industries Limited by 16.7% in the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after acquiring an additional 6,115,853 shares during the last quarter. Capital World Investors boosted its stake in Teva Pharmaceutical Industries Limited by 41.9% in the second quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock valued at $367,686,000 after acquiring an additional 3,268,200 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its stake in Teva Pharmaceutical Industries Limited by 32.3% in the second quarter. Alliancebernstein L.P. now owns 11,399,400 shares of the company’s stock valued at $378,688,000 after acquiring an additional 2,782,257 shares during the last quarter. 56.77% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.